← Back to Search

Preoperative Chemotherapy for Retroperitoneal Sarcoma(STRASS2 Trial)

Phase 3
Research Sponsored by European Organisation for Research and Treatment of Cancer - EORTC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically proven primary high risk leiomyosarcoma (LMS) or Liposarcoma (LPS) of retroperitoneal space or infra-peritoneal spaces of pelvis.
LMS: Any grade LMS can be included. Minimum size of LMS tumor should be 5 cm.
Must not have
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up8 years from first patient in
Awards & highlights
No Placebo-Only Group
Pivotal Trial

STRASS2 Trial Summary

This trialtests if chemo before surgery can help people with a certain type of cancer live longer.

Eligible Conditions
  • Retroperitoneal Sarcoma
  • Leiomyosarcoma
  • Liposarcoma

STRASS2 Trial Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below

STRASS2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 years from first patient in
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 years from first patient in for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Disease free survival
Secondary outcome measures
Distant metastases free survival
Local recurrence free survival
Overall survival (OS)
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

STRASS2 Trial Design

2Treatment groups
Experimental Treatment
Group I: Standard armExperimental Treatment1 Intervention
Surgery alone
Group II: Experimental armExperimental Treatment1 Intervention
Preoperative chemotherapy and surgery
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3

Find a Location

Who is running the clinical trial?

ECOG-ACRIN Cancer Research GroupNETWORK
113 Previous Clinical Trials
175,824 Total Patients Enrolled
Japan Clinical Oncology GroupOTHER
18 Previous Clinical Trials
4,391 Total Patients Enrolled
European Organisation for Research and Treatment of Cancer - EORTCLead Sponsor
407 Previous Clinical Trials
164,421 Total Patients Enrolled

Media Library

Surgery Clinical Trial Eligibility Overview. Trial Name: NCT04031677 — Phase 3
Retroperitoneal Sarcoma Research Study Groups: Standard arm, Experimental arm
Retroperitoneal Sarcoma Clinical Trial 2023: Surgery Highlights & Side Effects. Trial Name: NCT04031677 — Phase 3
Surgery 2023 Treatment Timeline for Medical Study. Trial Name: NCT04031677 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there opportunities for participators still available in this experiment?

"Indeed, the information on clinicaltrials.gov confirms that this trial is open and accepting participants. This research project was initially posted on January 20th 2021 and last updated on December 27th 2022; 250 volunteers are needed from two separate sites."

Answered by AI

How many participants are accepted into the clinical trial at this time?

"Affirmative. Clinicaltrials.gov data shows that this investigation, which was initially announced on January 20th 2021, is still recruiting individuals to participate. The clinical trial requires 250 participants from two medical centres."

Answered by AI

To what degree is the Experimental arm safe for human use?

"Our team has rated the safety of Experimental arm at a 3, indicating that there is existing clinical data substantiating its efficacy along with numerous reports validating its security."

Answered by AI
~133 spots leftby Apr 2027